Kaken Pharmaceutical Co (4521) AI Stock Analysis

• Market Cap: ¥151.46B
• Dividend Yield: 4.16%
• Average Volume (3M): 164.95K
• Price to Earnings (P/E): 93.6
• Beta (1Y): 0.31
• Revenue Growth: -5.99%
• EPS Growth: -96.04%
• Country: JP
• Employees: 1,135
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 10.71
• Shares Outstanding: 44,139,730
• 10 Day Avg. Volume: 176,660
• 30 Day Avg. Volume: 164,953
• PEG Ratio: 0.17
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 1.82
• P/FCF Ratio: 6.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 38.15
• Revenue Forecast (FY): ¥76.89B

• Rating: 80 Outperform
• Price Target: ¥4,865.00 ▲(31.06% Upside)
• Action: Reiterated Date: 09/17/25
• Date: Action: Reiterated 09/17/25

Kaken Pharmaceutical Co's strong financial performance and attractive valuation are the most significant factors contributing to its overall score. The company's stable technical indicators further support a positive outlook. However, historical volatility in revenue and cash flow suggests a need for cautious future planning.

Positive Factors

Balance Sheet Strength

Very low leverage (Debt-to-Equity 0.025), a strong equity ratio (80.16%) and ROE of 9.14% provide durable financial flexibility. This healthy capital structure supports multi-year R&D, licensing or M&A, and buffers the company against reimbursement shocks or cyclical pressures.

Negative Factors

Recent Revenue and EPS Contraction

Sharp reported declines in revenue (~-19%) and EPS (~-118%) indicate meaningful deterioration in near-term core performance. Such steep contractions can reflect product lifecycle, demand or reimbursement impacts that raise execution risk and may impair multi-year R&D and commercialization plans.

Kaken Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychom...

Read more

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychom...

How the Company Makes Money

Kaken Pharmaceutical makes money primarily by selling prescription pharmaceuticals, with revenue recognized from product shipments to wholesalers, distributors, and/or medical institutions (depending on channel structure). Its core revenue stream ...

Read more

Kaken Pharmaceutical makes money primarily by selling prescription pharmaceuticals, with revenue recognized from product shipments to wholesalers, distributors, and/or medical institutions (depending on channel structure). Its core revenue stream ...

Kaken Pharmaceutical Co Financial Statement Overview

Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	94.65B	94.03B	72.04B	72.98B	76.03B	74.98B
Gross Profit	58.08B	58.26B	38.54B	39.56B	41.58B	40.91B
EBITDA	20.34B	22.02B	12.57B	9.40B	16.38B	20.99B
Net Income	12.46B	13.95B	8.03B	5.44B	9.55B	13.40B
Balance Sheet
Total Assets	176.34B	190.42B	171.62B	166.33B	165.18B	165.62B
Cash, Cash Equivalents and Short-Term Investments	55.40B	70.08B	65.32B	74.26B	74.62B	77.31B
Total Debt	3.85B	3.85B	3.85B	3.85B	3.85B	3.85B
Total Liabilities	28.89B	37.78B	27.87B	29.49B	26.85B	29.36B
Stockholders Equity	147.45B	152.63B	143.75B	136.26B	137.75B	136.26B
Cash Flow
Free Cash Flow	0.00	25.64B	716.00M	7.27B	10.35B	12.41B
Operating Cash Flow	0.00	29.78B	2.58B	9.25B	13.34B	14.38B
Investing Cash Flow	0.00	-19.65B	-5.85B	-2.63B	-7.89B	-1.64B
Financing Cash Flow	0.00	-5.37B	-5.66B	-6.99B	-8.13B	-8.75B

Kaken Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3712.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4521, the sentiment is Positive. The current price of 3712 is below the 20-day moving average (MA) of 4142.44, below the 50-day MA of 4128.73, and below the 200-day MA of 3823.23, indicating a bullish trend. The MACD of 3.86 indicates Negative momentum. The RSI at 58.92 is Neutral, neither overbought nor oversold. The STOCH value of 48.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4521.

Kaken Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4521	80 Outperform	¥151.46B	93.62	-2.58%	4.16%	-5.99%	-96.04%
4547	79 Outperform	¥198.72B	14.92	6.70%	2.48%	13.11%	41.57%
4534	73 Outperform	¥121.82B	12.60	4.81%	2.34%	4.35%	48.30%
4569	69 Neutral	¥89.28B	8.41	―	3.36%	11.65%	93.46%
4553	67 Neutral	¥204.73B	5.05	12.02%	2.14%	9.32%	30.85%
4887	59 Neutral	¥222.52B	13.89	―	2.28%	12.78%	-105.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%